Non-SITC Educational Events

FACT Immune Effector Cellular Therapy Inspection and Accreditation Workshop

Nov. 9, 2017
7:30 a.m. - 5 p.m.
Gaylord National Hotel

This training workshop is designed to educate participants on two key perspectives: building quality into their immune effector cell programs and performing peer-based inspections. FACT’s mission is to improve the quality of cellular therapy programs and depends on volunteer experts to visit programs and assess their compliance with the Standards. This peer-review approach keeps FACT accreditation credible, relevant, and useful. Attendees will learn about the mission of FACT, principles of FACT Standards, the accreditation process, and basic inspection techniques.

Registration is free for current inspectors and approved inspector trainees. Physicians wishing to train to become an inspector for the FACT Immune Effector Cell Accreditation Program must meet prerequisite education and experience requirements, submit a satisfactory inspector application, attend an in-person training workshop, view online videos, and complete a test on the requirements.

To apply to become an inspector, submit an online application.

View meeting details and register here

Addressing Unmet Needs in Lung Cancer With Rational Immunotherapy-Based Approaches: Evidence and Practicalities

Nov. 10, 2017
Registration and Lunch: 12:15 - 12:45 p.m.
Symposium: 12:45 - 1:45 p.m.
Gaylord National Hotel

It is clear that immunotherapy has already become a key pillar in the treatment of advanced NSCLC, but new data have emerged recently that are showing potential for further changing clinical practice, and there are also a number of critical questions that still need to be answered by ongoing research. In the oncology community, there is a lot of interest in strategies that may expand on the benefits currently seen with immunotherapies in lung cancer. To that end, a wide range of single-agent and combinatorial immune-based treatment approaches are being explored in various settings and populations to assess their role and potential for further improving outcomes. Finding better biomarkers for predicting benefit from immunotherapies is another area where intense research efforts are underway. The most important aspect to consider is how to interpret the vast amount of accumulating evidence and translate it into everyday patient care in a rational and meaningful manner.

If you could benefit from a concise and focused overview of the present and future of immunotherapy in lung cancer, this Live Master Class and Practicum is for you! Drs. Naiyer Rizvi and Melissa Johnson will hold an interactive discussion highlighting the current state of the science as well as new promising directions. They will also debate what this means for clinicians, researchers, and patients, and provide practical guidance for effectively navigating the rapidly changing and complex lung cancer treatment landscape in the era of immuno-oncology.

For more information and to register, please visit: www.peerviewpress.com/ITClung17

Upon completion of this activity, participants should be better able to:

• Analyze the efficacy and safety of immunotherapies and immune-based combinations in different types and settings of lung cancer based on the evidence from the latest clinical trials
• Discuss the indications for and roles of immunotherapies and combinations in the treatment of different types and settings of lung cancer
• Integrate immunotherapies either as monotherapies or as part of rational combinations into treatment plans for appropriate patients with lung cancer according to the latest evidence and recommendations
• Refer patients with lung cancer to clinical trials assessing novel strategies with immunotherapies and combinations to further advance the field, address unmet needs, and improve patient outcomes

This activity has been designed to meet the educational needs of oncologists and other healthcare professionals as well as researchers involved in advancing the care of patients with lung cancer through optimal use of cancer immunotherapies.

This CME activity is jointly provided by Medical Learning Institute, Inc., and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.

Powering in-depth molecular and immune characterization of melanomas with heterogeneous PTEN expression via 3D Biology Technology: High Plex Multi-Analyte Profiling on FFPE with Spatial Resolution

Nov. 11, 2017
12:45 - 1:45 p.m.
Gaylord National Hotel

The field of melanoma has been transformed by the parallel development of effective immune and targeted therapies.  There is now strong evidence of cross-talk between oncogenic signaling pathways in tumors and the anti-tumor immune response, supporting the need for concurrent evaluation of immune and molecular phenotypes in patient samples.  Further, there is growing evidence of the heterogeneity of immune and molecular phenotypes between, and even within, tumors.  This presentation reveals details around the technology and discusses examples of studies in which Digital Spatial Profiling has been used to assess immune and molecular features to make insights into the pathogenesis of melanoma.

Speakers:

• Joseph Beechem, V.P. Research and Development, NanoString Technologies
• Mike Davies, M.D., Ph.D. Associate Professor and the Deputy Chairman of the Department of Melanoma Medical Oncology